Glycomimetics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Fairmount Funds Management LLC and its affiliates have increased their beneficial ownership in Crescent Biopharma, Inc. to 16.52% through recent share and warrant purchases.
Fairmount Funds Management LLC and its affiliates increased their beneficial ownership in Crescent Biopharma, Inc. to 18.53% through a $20 million private placement.
Fairmount Funds Management LLC and its affiliates have disclosed a significant 19.99% beneficial ownership in Crescent Biopharma, Inc. following the recent merger and associated financing activities, including a $44 million investment.
SCHEDULE 13D/A: Adage Capital Reduces Stake in GlycoMimetics (Now Crescent Biopharma) Below 5% Threshold Following Corporate Restructuring
Adage Capital Management, L.P. and its principals have filed an Amendment to their Schedule 13D, indicating their beneficial ownership in GlycoMimetics Inc. (now Crescent Biopharma, Inc.) has fallen below 5% following a merger, reverse stock split, and redomestication, leading to their voluntary exit from the reporting system.